All terms
Customer Notification Letter
Communication to users notifying them of a safety issue, corrective action, or important product information.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026
Definition
Required as part of most recalls and FSCAs, customer notification letters identify the affected product, describe the hazard, instruct on actions, and provide a response mechanism. Templates vary by regulator (FDA Recall Communication, EU FSN). Effective notices use clear subject lines, plain language, specific device identifiers (such as model, lot and UDI), a description of the risk and the required actions, and a response form to confirm receipt. FDA and EU authorities can review drafts, and authorities may publish them. Effectiveness checks track response rates, and follow-up notices may be needed. MDCG and IMDRF provide field safety notice templates. What the regulation says
Customer Notification Letters are a critical component of recall communications, mandated by regulators like the FDA in 21 CFR Part 7, Subpart C, and required for Field Safety Corrective Actions (FSCAs) under the EU MDR, as detailed in MDCG 2021-23. These letters ensure that affected parties are promptly informed about potential risks and necessary actions. The content and distribution are often guided by regulatory standards, such as those outlined by the FDA for recall communications or in the EU Medical Device Coordination Group (MDCG) guidance for Field Safety Notices (FSNs).What this means in practice
Effectiveness checks (e.g., response rate ≥ 90%) are scrutinized by FDA recall coordinators.Examples
- A medical device manufacturer issues a Customer Notification Letter to hospitals detailing a software bug in an infusion pump that could lead to incorrect dosage delivery, instructing them to isolate affected units and await a software update.
- Following a discovery of a sterility breach in a batch of single-use surgical instruments, a company sends a Customer Notification Letter to clinics advising them to cease use, quarantine the products, and arrange for their return.
- A diagnostic company distributes a Customer Notification Letter to laboratories about a lot of test reagents exhibiting false-positive results, providing instructions for disposal and replacement.
Common pitfalls
- •Failing to clearly articulate the specific hazard and the potential impact on patient health or user safety is a common pitfall.
- •Not providing explicit, actionable instructions for customers on what to do with the affected product can lead to poor recall effectiveness.
- •Using overly technical or ambiguous language that obscures the urgency and importance of the notification can hinder customer response.
- •Inadequate record-keeping of distributed letters and customer responses can lead to difficulties in demonstrating recall effectiveness to regulators.
- •Neglecting to follow up on non-responses or low response rates can result in enforcement actions for ineffective recalls.
Frequently asked questions
The primary purpose is to inform customers about a product defect or risk, instructing them on necessary actions to mitigate harm, and ensuring regulatory compliance during a recall or field safety corrective action.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Post-Market
· Same categoryPost-Market
5-Day Report
Expedited FDA MDR for events requiring remedial action to prevent unreasonable risk of substantial harm.
Post-Market
Annual Report (PMA)
Yearly report required for Class III PMA devices summarizing changes, complaints, and post-approval study status.
Post-Market
Electronic Medical Device Reporting(eMDR)
FDA's mandatory electronic submission system for Medical Device Reports.
Post-Market
Field Action vs Recall
Distinction between corrective field actions taken on devices in the field and FDA-defined recall events.
Cited by
Where this term appears across MedTech Terms.
Ecosystems (2)
Latest in MedTech
Sources
3 sourcesEvery citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2
Link health: 2 verified 1 unchecked· last checked 2026-06-20
FDA·1European Commission·1MDCG·1
- 121 CFR Part 7, RecallsTier 1 UncheckedFDAecfr.gov
- 2EUDAMED Public SiteTier 2 VerifiedEuropean Commissionec.europa.eu
- 3MDCG Vigilance GuidanceTier 2 VerifiedMDCGhealth.ec.europa.eu
Inline markers like [1] jump to the matching reference above.